Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zannad, F
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zannad, F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Evidence-based drug therapy for chronic heart failure

F Zannad*

Département des Maladies Cardio Vasculaires and Centre d'Investigations Cliniques INSERM-CHU, Université Henri Poincaré, Nancy, France

* Correspondence: Faiez Zannad, CIC INSERM-CHU, Hôpital Jeanne d'Arc, 54200 Dommartin Les Toul, Nancy, France.

Abstract

Evidence-based medicine requires that clinical benefits should be evaluated by ‘hard’ end-points (i.e. morbidity and mortality). ‘Soft’ intermediate end-points such as haemodynamic improvement are not always associated with improvements in quality of life or survival. Changes in clinical practice should be based on statistically significant effects on primary end-points, and not on subgroup analyses. Angiotensin-converting enzyme (ACE) inhibitors are of demonstrated benefit in all forms of congestive heart failure (CHF) with systolic dysfunction, when used at optimal doses. Beta-blockers confer additional quality of life and survival benefits. Spironolactone may be added in patients with severe CHF. In patients who are intolerant of ACE inhibitors, angiotensin II receptor blockers may be useful as a substitute. Despite the overwhelming data available, evidence-based recommendations for drug therapy are not widely implemented in CHF. Education and implementation programmes should be designed with the objective of combating ignorance, incredulity and inaction.

Key Words: Clinical trials • drug therapy • guidelines • heart failure

References

  1. Packer M, O'Connor C, Ghali J, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107–1114[Abstract/Free Full Text]
  2. Scherrer-Crosbie M, Cocca-Spofford D, Di Salvo TG, Semigran MJ, Dec GW, Picard MH. Effect of vesnarinone on cardiac function in patients with severe congestive heart failure. Am Heart J. 1998;136:769–777[CrossRef][Web of Science][Medline]
  3. Cohn J, Goldstein S, Greenberg B, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998;339:1810–1816[Abstract/Free Full Text]
  4. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patientsover 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–752[CrossRef][Web of Science][Medline]
  5. Pitt B, Poole-Wilson P, Segal R, et al, The ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–1587[CrossRef][Web of Science][Medline]
  6. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N EngI J Med. 1997;336:525–533
  7. Rector T, Tschumperlin L, Kubo S, et al. Use of the living with heart failure questionnaire to ascertain patients' perspectives on improvement in quality of life vs risk of drug-induced death. J Card Failure. 1995;1:201–206[CrossRef][Medline]
  8. Eur Heart J. 2001;22:1527–1560[Free Full Text]
  9. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuro-endocrine effects of introducing diuretics. Br Heart J. 1987;57:17–22[Abstract/Free Full Text]
  10. Cooper H, Dries D, Davis C, Shen Y, Domanski M. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311–1315[Abstract/Free Full Text]
  11. Heart Outcomes Prevention Evaluation (HOPE) Study. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet. 2000;355:253–259[CrossRef][Web of Science][Medline]
  12. Packer M, Bristow M, Cohn J, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N EngI J Med. 1996;334:1349–1355[Abstract/Free Full Text]
  13. Packer M, Coats A, Fowler M, et alfor the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658[Abstract/Free Full Text]
  14. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001–2007[CrossRef][Web of Science][Medline]
  15. Pitt B, Zannad F, Remme WJ, et al. Randomized aldactone evaluation study (BALES) mortality trial. N EngI J Med. 1999;341:709–717[Abstract/Free Full Text]
  16. Zannad F, Alla F, Dousset B, Perez A, Pitt B, The BALES investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation. 2000;102:2700–2706[Abstract/Free Full Text]
  17. Cohn J, Archibald D, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study. N Engl J Med. 1986;314:1547–1552[Abstract]
  18. Cohn J, Johnson G, Zeische S, et al. A comparison of enalapril with hydralazine-isosorbide denitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310[Abstract]
  19. Cardiosource Prospective Randomised Amlodipine Survival Evaluation II (PRAISE II). 2001. (accessed November 2001)http://www.cardiosource.com
  20. Khand A, Rankin A, Kaye G, Cleland J. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J. 2000;21:614–632[Abstract/Free Full Text]
  21. Singh S, Fletcher R, Fisher S, et al. for the survival trial of antiarrhythmic therapy in congestive heart failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 1995;333:77–82[Abstract/Free Full Text]
  22. Torp-Pedersen C, Moller M, Bloch-Thomsen P, et al. Dofetilide in patients with congestifve heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N EngI J Med. 1999;341:857–865[Abstract/Free Full Text]
  23. Loh E, Sutton M, Wun C, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N EngI J Med. 1997;336:251–257[Abstract/Free Full Text]
  24. Al-Khadra A, Salem D, Rand W, Udelson J, Smith J, Konstam M. Warfarin anticoatgulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;31:749–753[Abstract/Free Full Text]
  25. Echemann M, Briancon S, Juilliere Y, et al. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study). Eur J Heart Failure. 2001;: (in press)
  26. Cardiosource. The Warfarin Aspirin Study in Heart Failure (WASH Trial). 2000. (accessed November 2001)http://www.cardiosource.com
  27. Cardiosource. Warfarin Antiplatelet Therapy in Chronic Heart failure (WATCH Trial). 2001. (accessed November 2001)http://www.cardiosource.com
  28. Atrial Fibrillation Investigators. Risk factors fro stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457[Abstract/Free Full Text]
  29. Cleland J, Cowburn P, Falk R. Should all patients with atrial fibrillation receive warfarin? Evidence from randomized clinical trials. Eur Heart J. 1996;17:674–681[Free Full Text]
  30. Flather M, Yusuf S, Kober L, et al. Long term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575–1581[CrossRef][Web of Science][Medline]
  31. Cleland J. Improving patient outcomes in heart failure: evidence and barriers. Heart. 2000;84(suppl 1):8–10
  32. van Veldhuisen D, Charlesworth A, Crijns H, Lie K, Hampton J. Differences in drug treatment of chronic heart failure between European countries. Eur Heart J. 1999;20:666–672[Abstract/Free Full Text]
  33. Echemann M, Zannad F, Briancon S, et al. Determinants of angiotensin converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. Am Heart J. 2000;139:624–631[Web of Science][Medline]
  34. Mason J, Young P, Freemantle N, Hobbs R. Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction. BMJ. 2000;321:1113–1116[Abstract/Free Full Text]
  35. Blue L, Lang E, McMurray J, et al. Randomised controlled trial of specialist nurse intervention in heart failure. BMJ. 2001;323:715–718[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zannad, F
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zannad, F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?